Hematopoietic Stem Cell TransplantationTransplantation, HomologousCord Blood Stem Cell TransplantationGraft vs Host DiseaseStem Cell TransplantationTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousHematopoietic Stem CellsPeripheral Blood Stem Cell TransplantationGraft vs Leukemia EffectTransplantation ChimeraHistocompatibility TestingTissue DonorsTreatment OutcomeStem CellsBone Marrow TransplantationCytomegalovirus InfectionsMyeloablative AgonistsRetrospective StudiesBusulfanGraft vs Tumor EffectRecurrenceHistocompatibilityGraft SurvivalLeukemiaWhole-Body IrradiationVidarabineChimerismRoseolovirus InfectionsAspergillosisHematologic DiseasesLeukemia, Myeloid, AcuteCytomegalovirusRemission InductionImmunosuppressive AgentsSiblingsMyelodysplastic SyndromesAllograftsLymphocyte TransfusionPrecursor Cell Lymphoblastic Leukemia-LymphomaHLA AntigensFetal BloodSurvival RateHepatic Veno-Occlusive DiseaseSurvival AnalysisCombined Modality TherapyTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveT-LymphocytesAcute DiseaseMultiple MyelomaLymphocyte DepletionOpportunistic InfectionsAnemia, AplasticHematopoietic Stem Cell MobilizationDisease-Free SurvivalTransplantation ImmunologySalvage TherapyAntigens, CD34Minor Histocompatibility AntigensImmunocompromised HostFlow CytometryFollow-Up StudiesCyclophosphamideNeoplasm, ResidualTransplantation, IsogeneicAntilymphocyte SerumLymphoproliferative DisordersHematopoiesisMycosesCystitisBone Marrow CellsCell DifferentiationImmunosuppressionAntineoplastic Combined Chemotherapy ProtocolsEmbryonic Stem CellsLeukemic InfiltrationRisk FactorsMice, Inbred C57BLFatal OutcomeAdult Stem CellsPrognosisLeukemia, MyeloidGanciclovirMesenchymal Stem Cell TransplantationSevere Combined ImmunodeficiencyGraft RejectionMelphalanTransplantationVirus ActivationCells, CulturedPrimary MyelofibrosisStem Cell NicheCyclosporineIsoantigensCell TransplantationProspective StudiesCell LineageKidney Transplantation